



## **VGX Collaborators to present Chikungunya Vaccine Research at the 13<sup>th</sup> International Congress on Infectious Diseases**

Blue Bell, PA – June 12, 2008 –

VGX Pharmaceuticals Inc. (VGX) announced today that research data on the Company's SynCon™ DNA vaccine for Chikungunya virus (CHIKV) will be presented at the 13th International Congress on Infectious Diseases (ICID) as a part of an oral presentation. The Conference is sponsored by the International Society for Infectious Diseases and will take place June 19-22, 2008 at the Kuala Lumpur Convention Centre in Malaysia.

Dr. Karupiah Muthumani of the University of Pennsylvania, a VGX collaborator on the project, will deliver the oral presentation on June 20 titled "Immunogenicity of Novel Consensus-Based DNA Vaccines Against Chikungunya Virus. This presentation is part of the session entitled "New Insights to Infectious Diseases," and highlights the pre-clinical research and development of novel methodologies for a Chikungunya DNA vaccine using the Company's CELLECTRA® constant current electroporation device. The delivery of CHIKV antigens using intradermal electroporation (ID-EP) could be an important vaccination strategy as there are currently no vaccines or other specific treatments available for CHIKV.

CHIKV is a major emerging infectious disease indigenous to tropical Africa and Asia, where it is primarily transmitted to humans by the Aedes mosquito. Symptoms include fever, which lasts for 2 to 5 days. However, other symptoms, namely joint pain, intense headache, insomnia and an extreme degree of prostration last from 5 days to several months depending on age. "Chikungunya" is derived from the Makonde word meaning "that which bends up" in reference to the stooped posture developed as a result of the arthritic symptoms of the disease.

VGX Pharmaceuticals' SynCon™ DNA vaccine constructs are designed by aligning numerous primary sequences of the target antigens and choosing the most common amino acid or base pair at each site by using proprietary bioinformatics approaches. The SynCon™ DNA vaccines in combination with the CELLECTRA® delivery device provide greater levels of cross-reactive immune responses than those produced by more traditional vaccines.

**Cautionary Factors That May Affect Future Results** - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be

adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

### ***About VGX Pharmaceuticals***

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at [www.vgxp.com](http://www.vgxp.com).

### **Company Contact:**

Kevin W. Rassas  
Senior Vice-President  
Tel. 267.440.4208  
Fax 267.440.4242  
E-mail: [Rassas@vgxp.com](mailto:Rassas@vgxp.com)  
[www.vgxp.com](http://www.vgxp.com)